Focused On-demand Library for Chondroitin sulfate synthase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Chondroitin glucuronyltransferase 2; Chondroitin-polymerizing factor; Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II; N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase II; N-acetylgalactosaminyltransferase 2

Alternative UPACC:

Q8IZ52; B4DXU0; Q6UXD6; Q7L4G1; Q9H0F8; Q9H618


Chondroitin sulfate synthase 2, known by alternative names such as Chondroitin glucuronyltransferase 2 and N-acetylgalactosaminyltransferase 2, plays a crucial role in the biosynthesis of chondroitin sulfate. This enzyme exhibits beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity, essential for transferring glucuronic acid and N-acetylgalactosamine to the chondroitin polymer. It acts as a specific activating factor for CHSY1 in chondroitin polymerization, highlighting its significance in cellular structures.

Therapeutic significance:

Understanding the role of Chondroitin sulfate synthase 2 could open doors to potential therapeutic strategies. Its involvement in the synthesis of chondroitin sulfate, a key component of the extracellular matrix, suggests its potential in treating diseases related to cellular structure and function.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.